HYBIO(SZ:300199)2023-04-26 16:00Financial Performance - The company's operating revenue for Q1 2023 was ¥176,222,802.86, an increase of 5.39% compared to ¥167,212,356.18 in the same period last year[12]. - Net profit attributable to shareholders was ¥18,605,574.69, a significant turnaround from a loss of ¥57,654,813.97 in Q1 2022, representing a 132.27% increase[12]. - Total operating revenue for Q1 2023 was CNY 176,222,802.86, an increase from CNY 167,212,356.18 in Q1 2022, representing a growth of approximately 6.02%[36]. - Total comprehensive income amounted to 17,034,797.38, a significant decrease from -58,783,748.60 in the previous period[50]. - Basic and diluted earnings per share were both 0.02, compared to -0.06 in the prior period[50]. - Total profit amounted to 16,922,305.70, a recovery from a total loss of 58,298,888.42 in the previous year, showcasing a strong financial rebound[58]. Cash Flow - The net cash flow from operating activities was -¥37,499,158.99, a decline of 281.02% compared to a positive cash flow of ¥20,715,953.56 in the previous year[12]. - Cash inflows from operating activities totaled 196,699,999.31, slightly down from 200,624,150.18 in the previous period[51]. - Cash inflows from financing activities totaled 50,770,057.91, compared to 23,073,485.61 in the previous period[53]. - Net cash flow from financing activities was 2,107,882.75, a recovery from -19,092,072.43 in the prior period[53]. - The ending cash and cash equivalents balance was 75,620,737.93, down from 108,536,391.98 in the previous period[53]. Assets and Liabilities - Total assets at the end of Q1 2023 were ¥3,581,678,275.24, a slight decrease of 0.82% from ¥3,611,233,247.62 at the end of 2022[12]. - The company's total liabilities increased by 37.64% for current non-current liabilities due within one year, rising to ¥631,767,405.56 from ¥458,991,408.69[15]. - Non-current liabilities totaled 973,331,387.59 RMB, a decrease from 1,166,334,845.97 RMB[48]. - Total liabilities amounted to 2,255,517,801.30 RMB, compared to 2,314,291,599.94 RMB previously[48]. - The company's total equity attributable to shareholders was 1,300,195,773.92 RMB, an increase from 1,270,636,709.44 RMB[48]. Research and Development - Research and development expenses increased by 104.10% to ¥44,393,211.43, up from ¥21,750,925.60 in Q1 2022, primarily due to increased clinical trial costs[17]. - The company is focusing on expanding its market presence and developing new products, although specific details were not disclosed in the report[34]. - Future outlook includes continued investment in research and development to enhance product offerings and market competitiveness[34]. - Research and development expenses increased to 44,393,211.43, up from 21,750,925.60, reflecting the company's commitment to innovation and new product development[58]. Shareholder Information - Total number of common shareholders at the end of the reporting period was 62,213[42]. - The largest shareholder, Zeng Shaogui, holds 15.18% of shares, totaling 134,106,167 shares[42]. - The company completed the cancellation of 33,685,704 shares, reducing the total share capital from 916,927,040 shares to 883,241,336 shares[30]. Other Financial Metrics - The fair value change income from trading financial assets was ¥27,781,417.40, a significant recovery from a loss of -¥73,474,633.62 in the same quarter last year, marking a 137.81% improvement[17]. - The company reported a decrease in credit impairment losses to -1,766,646.00, compared to an increase of 3,035,076.61 in the prior period, indicating improved asset quality[58]. - The company experienced a significant increase in other income, which rose to 19,243,596.09 from 5,800,804.37, contributing positively to overall profitability[58]. - Financial expenses rose to 28,792,735.05, compared to 21,251,449.59, primarily driven by interest expenses of 27,907,368.98, which increased from 20,880,968.42[58].